表紙
市場調查報告書

主要7個國家的動脈瘤性蜘蛛膜下出血 (aSAH):市場分析·流行病學·市場預測 (∼2027年)

Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 524373
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
主要7個國家的動脈瘤性蜘蛛膜下出血 (aSAH):市場分析·流行病學·市場預測 (∼2027年) Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insight, Epidemiology and Market Forecast -2030
出版日期: 2020年04月01日內容資訊: 英文 200 Pages
簡介

本報告提供主要7個國家動脈瘤性蜘蛛膜下出血 (aSAH)的市場調查,彙整疾病的背景及概要,主要7個國家 (美國·德國·法國·義大利·西班牙·英國·日本) 的發生數變化與預測,目前治療方法,未滿足需求,主要藥物的簡介,國家·各藥物種類的市場規模變化與預測,市場影響因素分析等資料。

第1章 重要考察

第2章 市場概要

第3章 疾病的背景·概要:動脈瘤性蜘蛛膜下出血 (aSAH)

  • 簡介
  • 症狀
  • 病因·風險要素
  • 等級區分
  • 病理生理學
  • 診斷
  • 生物標記
  • 管理

第4章 流行病學·患者人口

  • 主要調查結果

第5章 主要7個國家的aSAH發生數

第6章 aSAH的流行病學:各國

  • 美國
    • 整體發生數
    • 發生數:男女
    • 發生數:各等級
    • 診斷病例數
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
      • 整體發生數
      • 發生數:男女
      • 發生數:各等級
      • 診斷病例數
  • 日本
    • 整體發生數
    • 發生數:男女
    • 發生數:各等級
    • 診斷病例數

第7章 治療流程·目前治療方法·臨床實際業務

第8章 未滿足需求

第9章 已上市藥物

  • Nymalize: Arbor Pharmaceuticals
    • 藥物概要
    • 作用機制
    • 法律規章上的里程碑
    • 優點及缺點
    • 安全性·有效性
    • 副作用
    • 產品簡介

第10章 新的藥物

  • 新的藥物比較
  • SFX-01: Evgen
  • Clazosentan: Actelion Pharmaceutical
    • 藥物概要
    • 法律規章上的里程碑
    • 臨床開發
    • 臨床試驗資訊
    • 安全性·有效性
    • 優點及缺點
    • 產品簡介

第11章 市場分析aSAH:主要7個國家

  • 主要調查結果
  • 整體市場規模
  • 美國
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第12章 市場成長的促進因素

第13章 市場障礙

第14章 附錄

第15章 DelveInsight的能力

第16章 免責聲明

第17章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0028

DelveInsight's 'Aneurysmal Subarachnoid Hemorrhage (aSAH)-Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (aSAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (aSAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Aneurysmal Subarachnoid Hemorrhage (aSAH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market size from 2017 to 2030. The report also covers current Aneurysmal Subarachnoid Hemorrhage (aSAH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Aneurysmal Subarachnoid Hemorrhage (aSAH) Disease Understanding and Treatment Algorithm

Aneurysmal Subarachnoid Hemorrhage (aSAH) Overview

Spontaneous (nontraumatic) subarachnoid hemorrhage (SAH) usually results from the rupture of a cerebral aneurysm. These aneurysms, which are located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of a ruptured aneurysm or polycystic kidney disease). Aneurysmal SAH is a worldwide health burden with high fatality and permanent disability rates. It is defined, according to the standard criteria, as an abrupt onset of a severe headache and/or loss of consciousness, with or without focal neurological signs, with CT, necropsy, or lumbar puncture, evidence of focal or generalized blood in the subarachnoid space.

The subarachnoid space is the area between the brain and the skull. It is filled with cerebrospinal fluid (CSF), which acts as a floating cushion to protect the brain. When blood is released into the subarachnoid space, it irritates the lining of the brain, increases pressure on the brain, and damages brain cells subsequently. At the same time, the area of the brain that received oxygen-rich blood from the affected artery previously is now deprived of blood, resulting in a stroke. Besides, SAH is frequently a sign of a ruptured aneurysm. Clotted blood and fluid buildup, enclosed within the rigid skull, increase the pressure that can crush the brain against the bone or cause it to shift and herniate. Moreover, blockage of the normal CSF circulation can enlarge the ventricles (hydrocephalus), causing confusion, lethargy, and loss of consciousness.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Diagnosis

The diagnosis of Aneurysmal Subarachnoid Hemorrhage (aSAH) is based on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests such as computerized tomography, lumbar pucture, and magnetic resonance imaging (MRI).

Subarachnoid hemorrhage (SAH) is a characterized by bleeding into the subarachnoid space around the brain and spinal cord, as shown in the images below; generally, the subarachnoid space is filled with clear, colorless cerebrospinal fluid (CSF). The most common causes of subarachnoid hemorrhage are head trauma and rupture of an intracranial aneurysm. As radiologic evaluation is essential for determining the prognosis and treatment of subarachnoid hemorrhage, radiologic interventional procedures have become increasingly crucial for the management of this condition.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Treatment

Once in the critical care setting, the main goals of treatment are the prevention of rebleeding, the prevention and management of vasospasm, and the treatment of other medical and neurologic complications. Blood pressure should be maintained within the normal limits, and if necessary, intravenous antihypertensive agents such as labetalol and nicardipine can be used. Once the aneurysm is secured, hypertension is allowed, but there is no agreement on the range. Analgesia is often required, and reversible agents such as narcotics are indicated. Calcium antagonists reduce the risk of poor outcome from ischemic complications, and oral nimodipine is currently recommended. Prolonged administration of antifibrinolytic agents reduces rebleeding but is associated with an increased risk of cerebral ischemia and systemic thrombotic events. Although early treatment of aneurysms has become the mainstay of rebleeding prevention, antifibrinolytic therapy may be used in the short term before aneurysm treatment.

Further, nimodipine is the only pharmacological intervention shown to improve outcome in SAH patients, although it has no impact on large-vessel vasospasm. The commonly used pain-relieving medications include morphine and a combination of codeine and paracetamol. The other medications that may be used to treat a subarachnoid hemorrhage include anticonvulsants, such as phenytoin-which may be used to prevent seizures (fits), and antiemetics, such as promethazine-which can help stop you feeling sick and vomiting. Currently, the two main therapeutic options for securing a ruptured aneurysm are microvascular neurosurgical clipping and endovascular coiling. Historically, microsurgical clipping has been the preferred method of treatment. Also, endovascular treatment of aneurysms has been available as an alternative to surgical therapy for the past 15 years.

It covers the details of conventional and current medical therapies available in the Aneurysmal Subarachnoid Hemorrhage (aSAH) market for the treatment of the various types of Aneurysmal Subarachnoid Hemorrhage (aSAH). It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight's Aneurysmal Subarachnoid Hemorrhage (aSAH) market report gives a thorough understanding of Aneurysmal Subarachnoid Hemorrhage (aSAH) by including details such as disease definition, comorbidities, causes, risk factors, pathogenesis, and diagnosis.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH), Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH), Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH), WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH), Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH), and Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) scenario of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030. The additional segments include Gender-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) and Hunt-Hess Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH).

Key Findings

This section provides glimpses of the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology in the 7MM.

  • In the 7MM, the total incident of Subarachnoid Hemorrhage (SAH) was estimated to be 63,072 cases in 2017 whereas the total incident of Aneurysmal Subarachnoid Hemorrhage (aSAH) was estimated to be 53,611.
  • According to the analysis, the estimated cases in WFNS grade-wise segmentation in 2017 for I-II, III, IV-V was 1,740, 305, and 1,196 respectively. The anticipated decrease in the grade wise segmentation in the forecast period is 1,393, 244 and 957 in Germany.
  • Several manifestations act as a contributor in course of development of aSAH. A total of 9,193, 3,940, 9,718, 10,112, 6,960 and 4,597 cases develop during aSAH i.e., Angiographic Vasospasm, Delayed ischemic neurologic deficit (DIND), Headache, Nausea or Vomiting, Loss of Conciousness and Nuchal Rigidity in 2017, which as per Delveinsight assessments will decrease to 8,391, 3,596, 8,870, 9,230, 6,353 and 4,195 cases, respectively, in 2030 in the US.
  • According to the analysis, the estimated cases in Fisher grade-wise segmentation in 2017 for I-II, III-IV is 468, and 1,930 respectively. The anticipated decrease in the grade wise segmentation in the forecast period is 374 and 1,545 (France).

Country Wise-Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology

The epidemiology segment also provides the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Drug Chapters

The drug chapter segment of the Aneurysmal Subarachnoid Hemorrhage (aSAH) report encloses the detailed analysis of Aneurysmal Subarachnoid Hemorrhage (aSAH) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Aneurysmal Subarachnoid Hemorrhage (aSAH) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Marketed Drugs

Nymalize (nimodipine): Arbor Pharmaceuticals

Nymalize (Nimodipine) is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. Nymalize is the only oral nimodipine solution approved by the US FDA. In September 2011, Orphan Product Development (OOPD) granted Nymalize, an oral nimodipine solution, orphan drug designation for the treatment of subarachnoid hemorrhage. In October 2015, orphan designation (EU/3/15/1554) was granted by the European Commission to for nimodipine for the treatment of aSAH.

Products detail in the report…

Aneurysmal Subarachnoid Hemorrhage (aSAH) Emerging Drugs

SFX-01: Evgen Pharma

SFX-01 is a synthetic form of sulforaphane stabilized by a ?-cyclodextrin ring and is the codename for the first product to use the Sulforadex technology. The drug is known to modulate key signaling pathways involved in cellular protection and inflammation. It is under development by Evgen Pharma and is being developed using Evgen's proprietary Technology, Sulforadex, which creates new and stable variants of sulforaphane, enabling it to be used as a first-time therapeutic. The US FDA has also granted Orphan drug designation for the use of stabilized sulforaphane in subarachnoid hemorrhage.

Clazosentan: Idorsia Pharmaceuticals

Clazosentan is an endothelin receptor antagonist in development as an intravenous infusion for cerebral vasospasm secondary to aSAH. Idorsia believes clazosentan can decrease the need for invasive intervention (i.e., angioplasty), which is currently used in such conditions at a high cost and with high medical risks. Currently, clazosentan has completed a Phase II study, REVERSE-which evaluated whether clazosentan has a rapid effect in reversing angiographically-confirmed cerebral vasospasm in patients with aSAH treated by endovascular coiling or surgical clipping. Clazosentan was granted orphan status in Europe in 2003 and the US in 2006.

GTX-104: Grace Therapeutics

GTX-104 is the injectable drug, designed to help people with SAH caused by a ruptured brain aneurysm, SAH is a rare and life-threatening medical emergency in which bleeding occurs in the subarachnoid space between the brain and the skull. This drug is under development by Grace Therapeutics which is in phase III pivotal study for the patients of SAH.

EG-1962: Edge Therapeutics/PDS Biotechnology Corporation

EG-1962 is a polymer-based microparticle containing nimodipine and calcium channel antagonists under development by Edge Therapeutics for the treatment of aSAH patients. A single dose of EG-1962 delivers high concentrations of nimodipine, the current standard of care, directly to the brain with sustained drug exposure over 21 days. EG-1962 utilizes Edge's proprietary, programmable, biodegradable polymer-based development platform, known as Precisa. In May 2016, Edge Therapeutics announced that the US FDA has granted Fast Track designation to its investigational product EG-1962 for the treatment of subarachnoid hemorrhage (SAH).

Products detail in the report…

Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Outlook

Currently, the treatment comprises of Nymalize, which is the only approved drug and mainstay of treatment for the patients with aSAH. Nymalize (Nimodipine) is the calcium channel antagonist with a powerful antihypertensive activity and a unique cerebrovascular profile. The commonly used pain-relieving medications include morphine and a combination of codeine and paracetamol. The other medications that may be used to treat a subarachnoid hemorrhage include anticonvulsants, such as phenytoin-which may be used to prevent seizures (fits), and antiemetics, such as promethazine-which can help stop you feeling sick and vomiting. Currently, the two main therapeutic options for securing a ruptured aneurysm are microvascular neurosurgical clipping and endovascular coiling.

The Aneurysmal Subarachnoid Hemorrhage (aSAH) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Aneurysmal Subarachnoid Hemorrhage (aSAH) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Aneurysmal Subarachnoid Hemorrhage (aSAH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Aneurysmal Subarachnoid Hemorrhage (aSAH) 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Aneurysmal Subarachnoid Hemorrhage (aSAH) 7MM market.

  • According to Delveinsight estimates, the United States accounts for the largest market size of Aneurysmal Subarachnoid Hemorrhage (aSAH), in comparison to Japan and EU5 (the United Kingdom, Germany, Italy, France, and Spain).
  • The market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the seven major markets is USD 155.47 Million in 2017.
  • Among 7MM, Japan accounts for the second highest market size during the forecast period 2017-2030, at a CAGR of 9.44% for the study period (2017-2030).

The United States Market Outlook

This section provides the total Aneurysmal Subarachnoid Hemorrhage (aSAH) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Aneurysmal Subarachnoid Hemorrhage (aSAH) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Aneurysmal Subarachnoid Hemorrhage (aSAH) market size and market size by therapies in Japan are provided.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Aneurysmal Subarachnoid Hemorrhage (aSAH) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Aneurysmal Subarachnoid Hemorrhage (aSAH) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Aneurysmal Subarachnoid Hemorrhage (aSAH) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Aneurysmal Subarachnoid Hemorrhage (aSAH) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Aneurysmal Subarachnoid Hemorrhage (aSAH), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Aneurysmal Subarachnoid Hemorrhage (aSAH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Aneurysmal Subarachnoid Hemorrhage (aSAH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market.

Report Highlights:

  • In the coming years, Aneurysmal Subarachnoid Hemorrhage (aSAH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Aneurysmal Subarachnoid Hemorrhage (aSAH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Aneurysmal Subarachnoid Hemorrhage (aSAH). Launch of emerging therapies will significantly impact the Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Aneurysmal Subarachnoid Hemorrhage (aSAH) Pipeline Analysis
  • Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Aneurysmal Subarachnoid Hemorrhage (aSAH) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Aneurysmal Subarachnoid Hemorrhage (aSAH) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Aneurysmal Subarachnoid Hemorrhage (aSAH) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Aneurysmal Subarachnoid Hemorrhage (aSAH) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Aneurysmal Subarachnoid Hemorrhage (aSAH) market size during the forecast period (2020-2030)?
  • At what CAGR, the Aneurysmal Subarachnoid Hemorrhage (aSAH) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Aneurysmal Subarachnoid Hemorrhage (aSAH) market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Aneurysmal Subarachnoid Hemorrhage (aSAH) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • What is the historical Aneurysmal Subarachnoid Hemorrhage (aSAH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Aneurysmal Subarachnoid Hemorrhage (aSAH) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to asperillosis?
  • Out of the above-mentioned countries, which country would have the highest incident population of Aneurysmal Subarachnoid Hemorrhage (aSAH) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the US and Europe?
  • What are the Aneurysmal Subarachnoid Hemorrhage (aSAH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • How many therapies are developed by each company for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aneurysmal Subarachnoid Hemorrhage (aSAH) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Aneurysmal Subarachnoid Hemorrhage (aSAH) and their status?
  • What are the key designations that have been granted for the emerging therapies for Aneurysmal Subarachnoid Hemorrhage (aSAH)?
  • What are the 7MM historical and forecasted market of Aneurysmal Subarachnoid Hemorrhage (aSAH)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Aneurysmal Subarachnoid Hemorrhage (aSAH).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Aneurysmal Subarachnoid Hemorrhage (aSAH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
  • To understand the future market competition in the Aneurysmal Subarachnoid Hemorrhage (aSAH) market.

Table of Contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 2017
  • 4.2 Market Share (%) Distribution of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 2030

5 Disease Background and Overview: Aneurysmal Subarachnoid Hemorrhage

  • 5.1 Introduction
  • 5.2 Risk Factors
  • 5.3 Clinical Presentation
    • 5.3.1 Cardiac Manifestations
    • 5.3.2 Neurogenic Pulmonary Edema (NPE)
    • 5.3.3 Hypertension
  • 5.4 Grading
    • 5.4.1 World Federation of Neurosurgeons SAH Scale (WFNS)
    • 5.4.2 The Hunt and Hess Scale
    • 5.4.3 Fisher Scale
  • 5.5 Pathophysiology
  • 5.6 Diagnosis
    • 5.6.1 Computerized tomography (CT scan)
    • 5.6.2 Lumbar puncture
    • 5.6.3 Magnetic resonance imaging (MRI)
    • 5.6.4 Aneurysm detection
  • 5.7 Management
    • 5.7.1 Acute Management
    • 5.7.2 Management of the ruptured aneurysm
    • 5.7.3 Rebleeding
    • 5.7.4 Critical care management
    • 5.7.5 DCI and vasospasm

6 Recognized Establishments

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 7 Major Markets Epidemiology
    • 7.2.1 Incidence of Subarachnoid Hemorrhage (SAH) in the 7MM
    • 7.2.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM
  • 7.3 United States
    • 7.3.1 Assumption and Rationale
    • 7.3.2 Incidence of Subarachnoid Hemorrhage (SAH) in the United States
    • 7.3.3 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
    • 7.3.4 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
    • 7.3.5 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
    • 7.3.6 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
    • 7.3.7 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States
  • 7.4 EU-5 Epidemiology
    • 7.4.1 Assumption and rationale
  • 7.5 Germany
    • 7.5.1 Incidence of Subarachnoid Hemorrhage (SAH) in Germany
    • 7.5.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the Germany
    • 7.5.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the Germany
    • 7.5.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany
    • 7.5.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany
    • 7.5.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany
  • 7.6 France
    • 7.6.1 Incidence of Subarachnoid Hemorrhage (SAH) in France
    • 7.6.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
    • 7.6.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
    • 7.6.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
    • 7.6.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
    • 7.6.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France
  • 7.7 Italy
    • 7.7.1 Incidence of Subarachnoid Hemorrhage (SAH) in Italy
    • 7.7.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
    • 7.7.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
    • 7.7.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
    • 7.7.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
    • 7.7.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy
  • 7.8 Spain
    • 7.8.1 Incidence of Subarachnoid Hemorrhage (SAH) in Spain
    • 7.8.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
    • 7.8.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
    • 7.8.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
    • 7.8.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
    • 7.8.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain
  • 7.9 United Kingdom
    • 7.9.1 Incidence of Subarachnoid Hemorrhage (SAH) in the United Kingdom
    • 7.9.2 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
    • 7.9.3 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
    • 7.9.4 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
    • 7.9.5 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
    • 7.9.6 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom
  • 7.10 Japan
    • 7.10.1 Assumption and Rationale
    • 7.10.2 Incidence of Subarachnoid Hemorrhage (SAH) in Japan
    • 7.10.3 Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
    • 7.10.4 Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
    • 7.10.5 WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
    • 7.10.6 Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan
    • 7.10.7 Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan

8 Treatment of Aneurysmal Subarachnoid hemorrhage (aSAH)

    • 8.1.1 Calcium channel blockers
    • 8.1.2 Pain-relieving medications
    • 8.1.3 Anticonvulsants
    • 8.1.4 Surgery
  • 8.2 Upcoming Therapies
  • 8.3 Treatment Guidelines for SAH
  • 8.4 Treatment of Delayed ischemic neurologic deficit (DIND) or delayed cerebral ischemia (DCI)
    • 8.4.1 Clearance of subarachnoid spaces
    • 8.4.2 Systemic targeting of angiographic vasospasm
    • 8.4.3 Local delivery
    • 8.4.4 Drugs with multidirectional effects/neuroprotection
    • 8.4.5 Microthrombosis
    • 8.4.6 Free radicals and inflammation
    • 8.4.7 Induced hypertension for the treatment of vasospasm
    • 8.4.8 Intra-Arterial Vasodilator Therapy
    • 8.4.9 Other Endovascular Techniques
    • 8.4.10 Cardiac output augmentation
    • 8.4.11 Clearance of subarachnoid spaces
    • 8.4.12 Triple H therapy
  • 8.5 Treatment algorithm
  • 8.6 Prevention of DCI
  • 8.7 Conclusion

9 Unmet Needs

10 Marketed Drugs

  • 10.1 Nymalize (nimodipine): Arbor Pharmaceuticals
    • 10.1.1 Drug Description
    • 10.1.2 Regulatory Milestones
    • 10.1.3 Other Developmental Activities
    • 10.1.4 Advantages and Disadvantages
    • 10.1.5 Safety and Efficacy
    • 10.1.6 Product Profile

11 Emerging Drugs

  • 11.1 Key Cross Competition
  • 11.2 SFX-01: Evgen Pharma
    • 11.2.1 Product Description
    • 11.2.2 Regulatory Milestones
    • 11.2.3 Clinical Development
    • 11.2.4 Safety and Efficacy
    • 11.2.5 Advantages and Disadvantages
    • 11.2.6 Product Profile
  • 11.3 Clazosentan: Idorsia Pharmaceuticals
    • 11.3.1 Product Description
    • 11.3.2 Regulatory Milestones
    • 11.3.3 Clinical Development
    • 11.3.4 Safety and Efficacy
    • 11.3.5 Advantages and Disadvantages
    • 11.3.6 Product Profile
  • 11.4 GTX-104: Grace Therapeutics
    • 11.4.1 Product Description
    • 11.4.2 Other Developmental Activity
    • 11.4.3 Product Profile
  • 11.5 EG-1962: Edge Therapeutics/PDS Biotechnology Corporation
    • 11.5.1 Product Description
    • 11.5.2 Regulatory Milestones
    • 11.5.3 Clinical Development
    • 11.5.4 Product Profile
  • 11.6 Nicaplant (nicardipine): BIT Pharma
    • 11.6.1 Product Description
    • 11.6.2 Regulatory Milestones
    • 11.6.3 Clinical Development
    • 11.6.4 Product Profile

12 Aneurysmal Subarachnoid Hemorrhage (aSAH): 7 Major Market Analysis

  • 12.1 Key Findings
  • 12.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM Countries
    • 12.1.1 Market Size by Therapies

13 7MM Market Outlook

14 United States Market Size

    • 14.1.1 Total Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 14.1.2 Market Size by Therapies

15 EU-5 Market Size

  • 15.1 Germany
    • 15.1.1 Total Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 15.1.2 Market Size by Therapies
  • 15.2 France
    • 15.2.1 Total Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 15.2.2 Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by Therapies
  • 15.3 Italy
    • 15.3.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 15.3.2 Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by Therapies
  • 15.4 Spain
    • 15.4.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 15.4.2 Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by Therapies
  • 15.5 United Kingdom
    • 15.5.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 15.5.2 Market Size by Therapies
  • 15.6 Japan Market Size
    • 15.6.1 Total Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)
    • 15.6.2 Market Size by Therapies

16 Conjoint Analysis

17 Access and Reimbursement

18 Case Reports

  • 18.1 Patient Story: Delayed Spinal Arachnoiditis Following Aneurysmal Subarachnoid Hemorrhage

19 Market Drivers

20 Market Barriers

21 Appendix

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

List of Tables

  • Table 1: Summary of Aneurysmal Subarachnoid Hemorrhage (aSAH) Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Risk Factors for the Formation of and Rupture of Intracranial Aneurysms
  • Table 3: Clinical Features of Intracranial Aneurysms Based on Location
  • Table 4: Hunt and Hess scale
  • Table 5: Incidence of Subarachnoid Hemorrhage (SAH) in the 7MM (2017-2030)
  • Table 6: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM (2017-2030)
  • Table 7: Incidence of Subarachnoid Hemorrhage (SAH) in the United States (2017-2030)
  • Table 8: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Table 9: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Table 10: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Table 11: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Table 12: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Table 13: Incidence of Subarachnoid Hemorrhage (SAH) in Germany (2017-2030)
  • Table 14: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Table 15: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Table 16: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Table 17: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Table 18: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Table 19: Incidence of Subarachnoid Hemorrhage (SAH) in France (2017-2030)
  • Table 20: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Table 21: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Table 22: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Table 23: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Table 24: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Table 25: Incidence of Subarachnoid Hemorrhage (SAH) in Italy (2017-2030)
  • Table 26: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Table 27: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Table 28: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Table 29: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Table 30: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Table 31: Incidence of Subarachnoid Hemorrhage (SAH) in Spain (2017-2030)
  • Table 32: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Table 33: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Table 34: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Table 35: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Table 36: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Table 37: Incidence of Subarachnoid Hemorrhage (SAH) in the United Kingdom (2017-2030)
  • Table 38: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Table 39: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Table 40: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Table 41: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Table 42: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Table 43: Incidence of Subarachnoid Hemorrhage (SAH) in Japan (2017-2030)
  • Table 44: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Table 45: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Table 46: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Table 47: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Table 48: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Table 49: Treatment Guidelines for Subarachnoid Hemorrhage
  • Table 50: Comparison of Emerging Drugs
  • Table 51: SFX-01, Clinical Trial Description, 2020
  • Table 52: Clazosentan, Clinical Trial Description, 2020
  • Table 53: EG-1962, Clinical Trial Description, 2020
  • Table 54: Nicaplant, Clinical Trial Description, 2020
  • Table 55: 7 Major Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in USD Million (2017-2030)
  • Table 56: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in the 7MM, in USD Million (2017-2030)
  • Table 57: United States Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 58: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in the US, in USD Million (2017-2030)
  • Table 59: Germany Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 60: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in Germany, in USD Million (2017-2030)
  • Table 61: France Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 62: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in France, in USD Million (2017-2030)
  • Table 63: Italy Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 64: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in Italy, in USD Million (2017-2030)
  • Table 65: Spain Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 66: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in Spain, in USD Million (2017-2030)
  • Table 67: United Kingdom Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 68: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in the United Kingdom, in USD Million (2017-2030)
  • Table 69: Japan Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH), USD Million (2017-2030)
  • Table 70: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: Aneurysmal subarachnoid hemorrhage SWOT Analysis
  • Figure 2: The intracranial arterial circulation showing the common locations of aneurysms.
  • Figure 3: Circle of Willis: The Circle of Willis is the joining area of several arteries at the bottom (inferior) side of the brain. At the Circle of Willis, the internal carotid arteries branch into smaller arteries that supply oxygenated blood to over 80% of the cerebrum.
  • Figure 4: Scale grading system used to quantify the amount of subarachnoid hemorrhage and intraventricular hemorrhage (IVH). The percentages in the circles refer to the risk of vasospasm. Grades III and IV in the scale are the ones with the higher risk to develop "symptomatic vasospasm."
  • Figure 5: Grading of SAH
  • Figure 6: Diagnostic Algorithm for Aneurysmal Subarachnoid Hemorrhage
  • Figure 7: CT scan for a SAH
  • Figure 8: Suggested scheme for diagnosing patients with suspected SAH
  • Figure 9: Incidence of Subarachnoid Hemorrhage (SAH) in the 7MM (2017-2030)
  • Figure 10: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM (2017-2030)
  • Figure 11: Incidence of Subarachnoid Hemorrhage (SAH) in the United States (2017-2030)
  • Figure 12: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Figure 13: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Figure 14: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Figure 15: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Figure 16: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States (2017-2030)
  • Figure 17: Incidence of Subarachnoid Hemorrhage (SAH) in Germany (2017-2030)
  • Figure 18: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Figure 19: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Figure 20: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Figure 21: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Figure 22: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany (2017-2030)
  • Figure 23: Incidence of Subarachnoid Hemorrhage (SAH) in France (2017-2030)
  • Figure 24: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Figure 25: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Figure 26: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Figure 27: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Figure 28: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France (2017-2030)
  • Figure 29: Incidence of Subarachnoid Hemorrhage (SAH) in Italy (2017-2030)
  • Figure 30: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Figure 31: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Figure 32: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Figure 33: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Figure 34: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy (2017-2030)
  • Figure 35: Incidence of Subarachnoid Hemorrhage (SAH) in Spain (2017-2030)
  • Figure 36: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Figure 37: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Figure 38: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Figure 39: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Figure 40: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain (2017-2030)
  • Figure 41: Incidence of Subarachnoid Hemorrhage (SAH) in the United Kingdom (2017-2030)
  • Figure 42: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Figure 43: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Figure 44: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Figure 45: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Figure 46: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United Kingdom (2017-2030)
  • Figure 47: Incidence of Subarachnoid Hemorrhage (SAH) in Japan (2017-2030)
  • Figure 48: Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Figure 49: Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Figure 50: WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Figure 51: Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Figure 52: Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan (2017-2030)
  • Figure 53: Stepwise approach to the treatment of active DCI from vasospasm
  • Figure 54: Stepwise approach to the treatment of active DCI from vasospasm
  • Figure 55: Unmet Needs of aSAH
  • Figure 56: 7 Major Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in USD Million (2017-2030)
  • Figure 57: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)by therapies in the 7MM, in USD Million (2017-2030)
  • Figure 58: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the United States, USD Millions (2017-2030)
  • Figure 59: Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in the US, in USD Million (2017-2030)
  • Figure 60: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Germany, USD Million (2017-2030)
  • Figure 61: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies, in Germany, in USD Million (2017-2030)
  • Figure 62: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in France, USD Million (2017-2030)
  • Figure 63: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies, in France, in USD Million (2017-2030)
  • Figure 64: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Italy, USD Million (2017-2030)
  • Figure 65: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies, in Italy, in USD Million (2017-2030)
  • Figure 66: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Spain, USD Million (2017-2030)
  • Figure 67: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in Spain, in USD Million (2017-2030)
  • Figure 68: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the UK, USD Million (2017-2030)
  • Figure 69: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in the UK, in USD Million (2017-2030)
  • Figure 70: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in Japan, USD Million (2017-2030)
  • Figure 71: Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) by therapies in Japan, in USD Million (2017-2030)
  • Figure 72: Market Drivers
  • Figure 73: Market Barriers